BioMarin Pharmaceutical Inc.
738 articles with BioMarin Pharmaceutical Inc.
-
Top 12 Biotech Companies Hiring Now
12/7/2021
Life sciences professionals are mixed as to whether the job market is in favor of the candidate or the employer. However, life sciences employers aren’t. -
BioMarin to Hold Virtual R&D Day at 11:00am ET Today
11/30/2021
BioMarin Pharmaceutical Inc. will host a virtual R&D Day beginning at 8:00am PT/11:00am ET , Tuesday, November 30, 2021.
-
BioMarin to Participate in Two Upcoming Virtual Investor Conferences - Nov 29, 2021
11/29/2021
BioMarin Pharmaceutical Inc. announced that management will participate in two upcoming virtual investor conferences.
-
BioMarin Receives FDA Approval for VOXZOGO™ (vosoritide) for Injection, Indicated to Increase Linear Growth in Children with Achondroplasia Aged 5 and Up with Open Growth Plates
11/19/2021
BioMarin Pharmaceutical Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to VOXZOGO™ (vosoritide) for Injection, indicated to increase linear growth in pediatric patients with achondroplasia five years of age and older with open epiphyses (growth plates).
-
BioMarin Pharmaceutical scored a first on Friday and provided an option for patients with a rare disease for which there is little recourse.
-
Mid-November is a relatively quiet period for the U.S. Food and Drug Administration in terms of its scheduled PDUFA dates. Read on for more.
-
BioMarin to Participate in Four Upcoming Virtual Investor Conferences - Oct 25, 2021
10/25/2021
BioMarin Pharmaceutical Inc. announced that management will participate in four upcoming virtual investor conferences.
-
BioMarin to Host Third Quarter 2021 Financial Results Conference Call and Webcast on Wednesday, October 27 at 4:30pm ET
10/12/2021
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, October 27, at 4:30 p.m. ET to discuss third quarter 2021 financial results and provide a general business update.
-
BioMarin Hires Industry Veterans to Fill Key Roles in R&D and Technical Operations
10/4/2021
Harold S. Bernstein, M.D., Ph.D. Named Senior Vice President, Chief Medical Officer and Head of Clinical Development Ganesh Vedantham, Ph.D. Named Senior Vice President, Technical Development
-
QurAlis' first piece of the puzzle is a protein called stathmin-2, which is encoded by the STMN2 gene.
-
Clinical Catch-Up: September 6-10
9/13/2021
It was a very busy week for clinical trial announcements, although there were only three that were COVID-19-related. Here’s a look. -
The oncogenicity and neurotoxicity risks of AAVs and possible mitigation strategies were the primary focus on Thursday.
-
Gene therapy clinical trials have been paused due to safety concerns, including the most recent one by BioMarin Pharmaceutical.
-
U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy Study in Adults with PKU Based on Interim Pre-clinical Study Findings
9/6/2021
BioMarin Pharmaceutical Inc. announced that the U.S Food and Drug Administration placed a clinical hold on the BMN 307 Phearless Phase 1/2 study.
-
European Commission Approves BioMarin's VOXZOGO® (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close
8/27/2021
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Commission (EC) has granted marketing authorization for VOXZOGO® (vosoritide), a once daily injection to treat achondroplasia in children from the age of 2 until growth plates are closed, which occurs after puberty when children reach final adult height.
-
BioMarin to Participate in Three Upcoming Virtual Investor Conferences
8/25/2021
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in three upcoming virtual investor conferences.
-
The U.S. FDA had a very packed calendar for this week, but almost everything on it was under a Priority Review pathway.
-
BioMarin Announces Second Quarter 2021 Financial Results and Corporate Updates
7/28/2021
BioMarin Pharmaceutical Inc. announced financial results for the second quarter ended June 30, 2021.
-
New Trial Data Call into Question Long-Term Efficacy of BioMarin’s Hemophilia A Gene Therapy
7/23/2021
Updated trial data show patients treated with BioMarin Pharmaceutical’s severe hemophilia A gene therapy expressed substantially lower factor VIII levels after five years compared with one year, calling into question the drug’s long-term benefits. -
BioMarin Announces Oral Presentation at ISTH 2021 Virtual Congress with 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec in Adults with Severe Hemophilia A, Demonstrating Continued, Durable Clinical Benefit
7/21/2021
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today new data for valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A, from its open-label Phase 1/2 study during an oral presentation at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress.